Lenalidomide Eugia

Lenalidomide, the active ingredient in Lenalidomide Eugia, is an immunomodulatory drug presented as an oral formulation for oral use. It is indicated for the treatment of certain hematologic malignancies, including multiple myeloma and myelodysplastic syndromes, and is prescribed for adult patients under specialist supervision.

GNH USA supplies Lenalidomide Eugia as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide, providing reliable access to this essential oncology medication through validated supply chains.

Lenalidomide is an immunomodulatory agent used in hematologic malignancies.

Multiple Myeloma: improves progression‑free survival and overall response rates in adult patients. Myelodysplastic Syndromes: reduces transfusion dependence and may improve peripheral blood counts.

Adverse reactions may vary in frequency and severity.

Common Side Effects: - Neutropenia - Thrombocytopenia - Fatigue - Nausea

Serious or Rare Side Effects: - Venous thromboembolism - Severe cutaneous reactions (e.g., Stevens‑Johnson syndrome) - Hepatic toxicity

Patients require careful monitoring and risk mitigation. - Monitor blood counts regularly: detect neutropenia or thrombocytopenia early. - Assess thrombotic risk: consider prophylactic anticoagulation when indicated. - Contraindicated in pregnancy: enforce effective contraception for both patient and partner. - Adjust dosing in renal impairment: follow specialist guidance for reduced clearance. - Counsel on potential drug‑specific toxicities: educate about signs of infection or liver injury. - Store at below 25°C: keep in the original pack, protect from moisture.

Lenalidomide may interact with several co‑administered medicines.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): increase systemic exposure. - Thalidomide: additive neurotoxicity risk. - Anticoagulants (e.g., warfarin): heightened bleeding potential.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin): reduce therapeutic levels. - NSAIDs: may increase gastrointestinal bleeding risk. - Digoxin: possible increase in serum concentration.